Cover Image
市场调查报告书

抗真菌药物的全球市场:药物类别(棘孢菌素,Azole,Polyenes,丙烯基胺,其他),感染疾病类别,投药的不同形状,不同症状,产业预测

Antifungal Drugs Market by Drug Type (Echinocandins, Azoles, Polyenes, Allylamines, and Others), Infection Type, Dosage form and Therapeutic Indication - Global Opportunity Analysis and Industry Forecast, 2017-2023

出版商 Allied Market Research 商品编码 529386
出版日期 内容信息 英文 190 Pages
商品交期: 最快1-2个工作天内
价格
Back to Top
抗真菌药物的全球市场:药物类别(棘孢菌素,Azole,Polyenes,丙烯基胺,其他),感染疾病类别,投药的不同形状,不同症状,产业预测 Antifungal Drugs Market by Drug Type (Echinocandins, Azoles, Polyenes, Allylamines, and Others), Infection Type, Dosage form and Therapeutic Indication - Global Opportunity Analysis and Industry Forecast, 2017-2023
出版日期: 2017年06月01日 内容信息: 英文 190 Pages
简介

本报告提供全球抗真菌药物市场相关调查分析,汇整市场概要,感染疾病类别,药物类别,不同症状,不同投药形状,各地区的考察,主要企业简介等相关信息。

第1章 简介

第2章 摘要整理

第3章 市场概要

  • 市场定义和范围
  • 主要调查结果
  • 波特的五力分析
  • 法律规范
  • 市场占有率分析
  • 市场动态
    • 促进要素
    • 抑制因素
    • 机会

第4章 抗真菌药物市场:感染疾病类别

  • 概要
  • 表格在真菌感染
  • 全身真菌感染

第5章 抗真菌药物市场:药物类别

  • 概要
  • 棘孢菌素
  • Azole
  • Polyenes
  • 丙烯基胺
  • 其他

第6章 抗真菌药物市场:不同症状

  • 概要
  • 麴菌症
  • 皮肤丝状菌症
  • 念珠菌感染
  • 其他

第7章 抗真菌药物市场:不同投药形状

  • 概要
  • 粉末
  • 软膏
  • 其他

第8章 抗真菌药物市场:各地区

  • 概要
  • 北美
  • 欧洲
  • 亚太地区
  • 南美/中东/非洲

第9章 企业简介

目录
Product Code: LI 172370

Antifungal drugs are used to treat fungal infections, which occur due to unclean, humid, and unhygienic environments. These infections are caused by organisms, which live by feeding on living tissue and are commonly known as dermatophytes that are responsible for the infection of hair, skin and nail as they can utilize keratin. In addition, fungal infections can cause harm to superficial (skin, mouth, and vagina) and systemic parts of the body (lungs, bones, brain, eyes, and others) Some of the common fungal infections such as athlete's foot, fungal meningitis, ringworm and other infections can be treated by antifungal drugs that work by killing of the fungal cell breaking the contents of the cell. These cells eventually leak out and results in the death of the cell, which also prevents the cell to grow further, thus preventing the infection. The global antifungal drugs market was valued at $13,719 million in 2016, and is expected to reach at $17,718 million by 2023, registering a CAGR of 3.7% from 2017 to 2023.

There are various modes of anti-fungal drug delivery that increases adoption of this products leading to high growth of this market. In addition, absorption of drugs works differently for each individual. Hence, advancement in drug delivery technology is expected to boost the growth of the global antifungal drug market. Further, growing incidence and prevalence rate of infectious diseases and growth in population of immunocompromised (prone to infectious diseases) individuals enhance the growth of this market. Furthermore, presence of alternative therapies and slow growth of medical infrastructure in emerging economies, such as China and India, hinder the market growth during the forecast period.

The global antifungal drugs market is segmented based on drug type, therapeutic indications, infection type, and geography. Based on drug type, the market is divided into echinocandins, azoles, polyenes, allylamines, and other drugs. Further, based on therapeutic indications, it is classified into aspergillosis, dermatophytosis, candidiasis, others. Based on infection type, the market is bifurcated into superficial and systemic antifungals.

Geographically, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA. North America accounted for the highest market share in 2016, and is expected to maintain the dominance throughout the forecast period. This is attributed to the increase in prevalence of fungal infections and growth in development of antifungal biopharmaceuticals, However, Asia-Pacific is expected to emerge as a lucrative area with maximum growth potential, due to the improvement in healthcare facilities, available disposable income, and rapid development of economic conditions.

KEY MARKET BENEFITS:

  • The study provides an in-depth analysis of the global antifungal drugs market, with current trends and future estimations to elucidate the imminent investment pockets.
  • Comprehensive analysis of factors that drive and restrict the market growth is provided.
  • Comprehensive quantitative analysis of the industry from 2016 to 2023 is provided to enable stakeholders to capitalize on the prevailing market opportunities.
  • Extensive analysis of the key segments of the industry, which helps understand the type of products and technologies used globally, is also included.
  • Key market players and their strategies are provided to understand the competitive outlook of the market.

KEY MARKET SEGMENTS:

By Drug Type

  • Echinocandins
    • Caspofungin
    • Micafungin
    • Anidulafungin
    • Others
  • Azoles
    • Imidazoles
    • Voriconazole
    • Thiazoles
    • Others
  • Polyenes
    • Amphotericin B
    • Candicidin
    • Hamycin
    • Natamycin
    • Others
  • Allylamines
    • Butenafine
    • Terbinafine
    • Naftifine
    • Others

By Infection Type

  • Superficial Antifungal Infections
  • Systemic Antifungal Infections
  • By Therapeutic Indications
  • Aspergillosis
  • Dermatophytosis
  • Candidiasis
  • Others

By Dosage Forms

  • Powders
  • Ointments
  • Drugs
  • Others

By Geography

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • U.K.
    • France
    • Germany
    • Italy
    • Spain
    • Rest of Europe
  • Asia-pacific
    • Japan
    • China
    • India
    • Australia
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • Argentina
    • Egypt
    • Israel
    • South Africa
    • Rest of LAMEA

KEY PLAYERS PROFILED:

  • Pfizer Inc.
  • Sanofi S.A.
  • Gilead Sciences, Inc.
  • Merck & Co., Inc.
  • Scynexis Inc.
  • Novartis International AG
  • Abbott Laboratories
  • Bayer AG
  • Enzon Pharmaceuticals, Inc.
  • GlaxoSmithKline Plc.

The other players in the value chain include (profiles not included in the report)

  • Sigma-Aldrich Corporation
  • Agilent Technologies, Inc.
  • Beckman Coulter, Inc. (a subsidiary of Danaher Corporation)
  • Tecan Group
  • Astellas Pharma, Inc.
  • Basilea Pharmaceutical Ltd.
  • Valeant Pharmaceuticals International, Inc.
  • Kramer Laboratories

Table of Contents

CHAPTER 1 INTRODUCTION

  • 1.1. REPORT DESCRIPTION
  • 1.2. KEY BENEFITS
  • 1.3. KEY MARKET SEGMENTS
  • 1.4. RESEARCH METHODOLOGY
    • 1.4.1. Secondary research
    • 1.4.2. Primary research
    • 1.4.3. Analyst tools & models

CHAPTER 2 EXECUTIVE SUMMARY

  • 2.1. CXO PERSPECTIVE

CHAPTER 3 MARKET OVERVIEW

  • 3.1. MARKET DEFINITION AND SCOPE
  • 3.2. KEY FINDINGS
    • 3.2.1. Top investment pockets
    • 3.2.2. Top winning strategies
  • 3.3. PORTERS FIVE FORCES ANALYSIS
  • 3.4. REGULATORY FRAMEWORK
  • 3.5. MARKET SHARE ANALYSIS, 2016
  • 3.6. MARKET DYNAMICS
    • 3.6.1. Drivers
      • 3.6.1.1. Increasing prevalence of fungal infection
      • 3.6.1.2. Rising awareness levels pertaining to myriad fungal infections
      • 3.6.1.3. Favorable government funds to combat the antifungal diseases
    • 3.6.2. Restraints
      • 3.6.2.1. Growing population with antifungal drug resistance
      • 3.6.2.2. Presence of counterfeit drugs and side effects of antifungal drugs
    • 3.6.3. Opportunities
      • 3.6.3.1. Patent expirations and increasing funding from public & private organizations

CHAPTER 4 ANTIFUNGAL DRUGS MARKET, BY INFECTION TYPE

  • 4.1. OVERVIEW
    • 4.1.1. Market size and forecast
  • 4.2. SUPERFICIAL ANTIFUNGAL INFECTION
    • 4.2.1. Key market trends
    • 4.2.2. Growth factors and opportunities
    • 4.2.3. Market size and forecast
  • 4.3. SYSTEMIC ANTIFUNGAL INFECTION
    • 4.3.1. Key market trends
    • 4.3.2. Growth factors and opportunities
    • 4.3.3. Market size and forecast

CHAPTER 5 ANTIFUNGAL DRUGS MARKET, BY DRUG TYPE

  • 5.1. OVERVIEW
    • 5.1.1. Market size and forecast
  • 5.2. ECHINOCANDINS
    • 5.2.1. Market size and forecast
    • 5.2.2. Micafungin
      • 5.2.2.1. Market size and forecast
    • 5.2.3. Caspofungin
      • 5.2.3.1. Market size and forecast
    • 5.2.4. Anidulafungin
      • 5.2.4.1. Market size and forecast
    • 5.2.5. Others
      • 5.2.5.1. Market size and forecast
  • 5.3. AZOLES
    • 5.3.1. Market size and forecast
    • 5.3.1. Imidazoles
      • 5.3.1.1. Market size and forecast
    • 5.3.2. Voricanazole
      • 5.3.2.1. Market size and forecast
    • 5.3.3. Thiazoles
      • 5.3.3.1. Market size and forecast
    • 5.3.4. Others
      • 5.3.4.1. Market size and forecast
  • 5.4. POLYENES
    • 5.4.1. Market size and forecast
    • 5.4.2. Amphotericin B
      • 5.4.2.1. Market size and forecast
    • 5.4.3. Candicidin
      • 5.4.3.1. Market size and forecast
    • 5.4.4. Hamycin
      • 5.4.4.1. Market size and forecast
    • 5.4.5. Natamycin
      • 5.4.5.1. Market size and forecast
    • 5.4.6. Others
      • 5.4.6.1. Market size and forecast
  • 5.5. ALLYLAMINES
    • 5.5.1. Market size and forecast
    • 5.5.1. Terbinafine
      • 5.5.1.1. Market size and forecast
    • 5.5.2. Butenafine
      • 5.5.2.1. Market size and forecast
    • 5.5.3. Naftifine
      • 5.5.3.1. Market size and forecast
  • 5.6. OTHERS
    • 5.6.1. Market size and forecast

CHAPTER 6 ANTIFUNGAL DRUGS MARKET, BY THERAPEUTIC INDICATIONS

  • 6.1. OVERVIEW
    • 6.1.1. Market size and forecast
  • 6.2. ASPERGILLOSIS
    • 6.2.1. Market size and forecast
  • 6.3. DERMATOPHYTOSIS
    • 6.3.1. Market size and forecast
  • 6.4. CANDIDIASIS
    • 6.4.1. Market size and forecast
  • 6.5. OTHERS
    • 6.5.1. Market size and forecast

CHAPTER 7 ANTIFUNGAL DRUGS MARKET, BY DOSAGE FORMS

  • 7.1. OVERVIEW
    • 7.1.1. Market size and forecast
  • 7.2. POWDER
    • 7.2.1. Market size and forecast
  • 7.3. OINTMENTS
    • 7.3.1. Market size and forecast
  • 7.4. DRUGS
    • 7.4.1. Market size and forecast
  • 7.5. OTHERS
    • 7.5.1. Market size and forecast

CHAPTER 8 ANTIFUNGAL DRUGS MARKET, BY GEOGRAPHY

  • 8.1. OVERVIEW
    • 8.1.1. Market size and forecast
  • 8.2. NORTH AMERICA
    • 8.2.1. Key market trends
    • 8.2.2. Key growth factors and opportunities
    • 8.2.3. Market size and forecast
      • 8.2.3.1. U.S. market size and forecast
      • 8.2.3.2. Mexico market size and forecast
      • 8.2.3.3. Canada market size and forecast
  • 8.3. EUROPE
    • 8.3.1. Key market trends
    • 8.3.2. Key growth factors and opportunities
    • 8.3.3. Market size and forecast
      • 8.3.3.1. UK market size and forecast
      • 8.3.3.2. France market size and forecast
      • 8.3.3.3. Germany market size and forecast
      • 8.3.3.4. Italy market size and forecast
      • 8.3.3.5. Spain market size and forecast
      • 8.3.3.6. Rest of Europe market size and forecast
  • 8.4. ASIA-PACIFIC
    • 8.4.1. Key market trends
    • 8.4.2. Key growth factors and opportunities
    • 8.4.3. Market size and forecast
      • 8.4.3.1. Japan market size and forecast
      • 8.4.3.2. China market size and forecast
      • 8.4.3.3. India market size and forecast
      • 8.4.3.4. Australia market size and forecast
      • 8.4.3.5. Rest of Asia-Pacific market size and forecast
  • 8.5. LAMEA
    • 8.5.1. Key market trends
    • 8.5.2. Key growth factors and opportunities
    • 8.5.3. Market size and forecast
      • 8.5.3.1. Brazil market size and forecast
      • 8.5.3.2. Argentina market size and forecast
      • 8.5.3.3. Saudi Arabia market size and forecast
      • 8.5.3.4. South Africa market size and forecast
      • 8.5.3.5. Rest of LAMEA market size and forecast

CHAPTER 9 COMPANY PROFILES

  • 9.1. PFIZER INC.
    • 9.1.1. Company overview
    • 9.1.2. Company snapshot
    • 9.1.3. Operating business segments
    • 9.1.4. Business performance
    • 9.1.5. Key strategic moves and developments
  • 9.2. SANOFI S.A
    • 9.2.1. Company overview
    • 9.2.2. Company snapshot
    • 9.2.3. Operating business segments
    • 9.2.4. Business performance
    • 9.2.5. Key strategic moves and developments
  • 9.3. GILEAD SCIENCES INC.
    • 9.3.1. Company overview
    • 9.3.2. Company snapshot
    • 9.3.3. Operating business segments
    • 9.3.4. Business performance
    • 9.3.5. Key strategic moves and developments
  • 9.4. MERCK & CO., INC.
    • 9.4.1. Company overview
    • 9.4.2. Company snapshot
    • 9.4.3. Operating business segments
    • 9.4.4. Business performance
    • 9.4.5. Key strategic moves and developments
  • 9.5. NOVARTIS INTERNATIONAL AG
    • 9.5.1. Company overview
    • 9.5.2. Company snapshot
    • 9.5.3. Operating business segments
    • 9.5.4. Business performance
    • 9.5.5. Key strategic moves and developments
  • 9.6. ABBOTT LABORATORIES
    • 9.6.1. Company overview
    • 9.6.2. Company snapshot
    • 9.6.3. Operating business segments
    • 9.6.4. Business performance
    • 9.6.5. Key strategic moves and developments
  • 9.7. BAYER AG
    • 9.7.1. Company overview
    • 9.7.2. Company snapshot
    • 9.7.3. Operating business segments
    • 9.7.4. Business performance
    • 9.7.5. Key strategic moves and developments
  • 9.8. SCYNEXIS INC.
    • 9.8.1. Company overview
    • 9.8.2. Company snapshot
    • 9.8.3. Operating business segments
    • 9.8.4. Business performance
    • 9.8.5. Key strategic moves and developments
  • 9.9. ENZON PHARMACEUTICALS INC.
    • 9.9.1. Company overview
    • 9.9.2. Company snapshot
    • 9.9.3. Operating business segments
    • 9.9.4. Business performance
    • 9.9.5. Key strategic moves and developments
  • 9.10. GLAXOSMITHKLINE PLC
    • 9.10.1. Company overview
    • 9.10.2. Company snapshot
    • 9.10.3. Operating business segments
    • 9.10.4. Business performance
    • 9.10.5. Key strategic moves and developments

List of Tables

  • TABLE 1. GLOBAL ANTIFUNGAL DRUGS MARKET, BY INFECTION TYPE, 2016-2023 ($MILLION)
  • TABLE 2. GLOBAL SUPERFICIAL ANTIFUNGAL INFECTION MARKET, BY REGION, 2016-2023 ($MILLION)
  • TABLE 3. GLOBAL SYSTEMIC ANTIFUNGAL INFECTION MARKET, BY REGION, 2016-2023 ($MILLION)
  • TABLE 4. GLOBAL ANTIFUNGAL DRUGS MARKET, BY DRUG TYPE, 2016-2023 ($MILLION)
  • TABLE 5. GLOBAL ANTIFUNGAL DRUGS MARKET FOR ECHINOCANDINS, BY TYPE, 2016-2023 ($MILLION)
  • TABLE 6. GLOBAL ANTIFUNGAL DRUGS MARKET FOR ECHINOCANDINS, BY REGION, 2016-2023 ($MILLION)
  • TABLE 7. GLOBAL ECHINOCANDINS ANTIFUNGAL DRUGS MARKET FOR MICAFUNGIN, BY REGION, 2016-2023 ($MILLION)
  • TABLE 8. GLOBAL ECHINOCANDINS ANTIFUNGAL DRUGS MARKET FOR CASPOFUNGIN, BY REGION, 2016-2023 ($MILLION)
  • TABLE 9. GLOBAL ECHINOCANDINS ANTIFUNGAL DRUGS MARKET FOR ANIDULAFUNGIN, BY REGION, 2016-2023 ($MILLION)
  • TABLE 10. GLOBAL ECHINOCANDINS ANTIFUNGAL DRUGS MARKET FOR OTHER DRUGS, BY REGION, 2016-2023 ($MILLION)
  • TABLE 11. GLOBAL ANTIFUNGAL DRUGS MARKET FOR AZOLES, BY DRUG TYPE, 2016-2023 ($MILLION)
  • TABLE 12. GLOBAL ANTIFUNGAL DRUGS MARKET FOR AZOLES, BY REGION, 2016-2023 ($MILLION)
  • TABLE 13. GLOBAL AZOLES ANTIFUNGAL DRUGS MARKET FOR IMIDAZOLES, BY REGION, 2016-2023 ($MILLION)
  • TABLE 14. GLOBAL AZOLES ANTIFUNGAL DRUGS MARKET FOR VORICANAZOLE, BY REGION, 2016-2023 ($MILLION)
  • TABLE 15. GLOBAL AZOLES ANTIFUNGAL DRUGS MARKET FOR THIAZOLES, BY REGION, 2016-2023 ($MILLION)
  • TABLE 16. GLOBAL AZOLES ANTIFUNGAL DRUGS MARKET FOR OTHER DRUGS, BY REGION, 2016-2023 ($MILLION)
  • TABLE 17. GLOBAL ANTIFUNGAL DRUGS MARKET FOR POLYENES, BY DRUG TYPE, 2016-2023 ($MILLION)
  • TABLE 18. GLOBAL ANTIFUNGAL DRUGS MARKET FOR POLYENES, BY REGION, 2016-2023 ($MILLION)
  • TABLE 19. GLOBAL POLYENES ANTIFUNGAL DRUGS MARKET FOR AMPHOTERICIN B, BY REGION, 2016-2023 ($MILLION)
  • TABLE 20. GLOBAL POLYENES ANTIFUNGAL DRUGS MARKET FOR CANDICIDIN, BY REGION, 2016-2023 ($MILLION)
  • TABLE 21. GLOBAL POLYENES ANTIFUNGAL DRUGS MARKET FOR HAMYCIN, BY REGION, 2016-2023 ($MILLION)
  • TABLE 22. GLOBAL POLYENES ANTIFUNGAL DRUGS MARKET FOR NATAMYCIN, BY REGION, 2016-2023 ($MILLION)
  • TABLE 23. GLOBAL POLYENES ANTIFUNGAL DRUGS MARKET FOR OTHER DRUGS, BY REGION, 2016-2023 ($MILLION)
  • TABLE 24. GLOBAL ANTIFUNGAL DRUGS FOR ALLYLAMINES MARKET, BY DRUG TYPE, 2016-2023 ($MILLION)
  • TABLE 25. GLOBAL ANTIFUNGAL DRUGS FOR ALLYLAMINES MARKET, BY REGION, 2016-2023 ($MILLION)
  • TABLE 26. GLOBAL ALLYLAMINES ANTIFUNGAL DRUGS MARKET FOR TERBINAFINE, BY REGION, 2016-2023 ($MILLION)
  • TABLE 27. GLOBAL ALLYLAMINES ANTIFUNGAL DRUGS MARKET FOR BUTENAFINE, BY REGION, 2016-2023 ($MILLION)
  • TABLE 28. GLOBAL ALLYLAMINES ANTIFUNGAL DRUGS MARKET FOR NAFTIFINE, BY REGION, 2016-2023 ($MILLION)
  • TABLE 29. GLOBAL ANTIFUNGAL DRUGS MARKET FOR OTHER, BY REGION, 2016-2023 ($MILLION)
  • TABLE 30. GLOBAL ANTIFUNGAL DRUGS MARKET, BY THERAPEUTIC INDICATIONS, 2016-2023 ($MILLION)
  • TABLE 31. GLOBAL ANTIFUNGAL DRUGS MARKET FOR ASPERGILLOSIS, BY REGION, 2016-2023 ($MILLION)
  • TABLE 32. GLOBAL ANTIFUNGAL DRUGS MARKET FOR DERMATOPHYTOSIS, BY REGION, 2016-2023 ($MILLION)
  • TABLE 33. GLOBAL ANTIFUNGAL DRUGS MARKET FOR CANDIDIASIS, BY REGION, 2016-2023 ($MILLION)
  • TABLE 34. GLOBAL ANTIFUNGAL DRUGS MARKET FOR THERAPEUTIC INDICATIONS BY REGION, 2016-2023 ($MILLION)
  • TABLE 35. GLOBAL ANTIFUNGAL DRUGS MARKET, BY DOSAGE FORMS, 2016-2023 ($MILLION)
  • TABLE 36. GLOBAL ANTIFUNGAL DRUGS MARKET FOR POWDER, BY REGION, 2016-2023 ($MILLION)
  • TABLE 37. GLOBAL ANTIFUNGAL DRUGS MARKET FOR OINTMENTS, BY REGION, 2016-2023 ($MILLION)
  • TABLE 38. GLOBAL ANTIFUNGAL DRUS MARKET FOR DRUGS, BY REGION, 2016-2023 ($MILLION)
  • TABLE 39. GLOBAL ANTIFUNGAL DRUGS MARKET FOR OTHER DOSAGE FORMS, BY REGION, 2016-2023 ($MILLION)
  • TABLE 40. GLOBAL ANTIFUNGAL DRUGS MARKET, BY REGION, 2016-2023 ($MILLION)
  • TABLE 41. NORTH AMERICA ANTIFUNGAL DRUGS MARKET, BY COUNTRY, 2016-2023 ($MILLION)
  • TABLE 42. NORTH AMERICA ANTIFUNGAL DRUGS MARKET, BY INFECTION TYPE, 2016-2023 ($MILLION)
  • TABLE 43. NORTH AMERICA ANTIFUNGAL DRUGS MARKET, BY DRUG TYPE, 2016-2023 ($MILLION)
  • TABLE 44. NORTH AMERICA ANTIFUNGAL DRUGS MARKET, BY THERAPEAUTIC INDICATION, 2016-2023 ($MILLION)
  • TABLE 45. NORTH AMERICA ANTIFUNGAL DRUGS MARKET, BY DOSAGE FORMS, 2016-2023 ($MILLION)
  • TABLE 46. EUROPE ANTIFUNGAL DRUGS MARKET, BY COUNTRY, 2016-2023 ($MILLION)
  • TABLE 47. EUROPE ANTIFUNGAL DRUGS MARKET, BY INFECTION TYPE, 2016-2023 ($MILLION)
  • TABLE 48. EUROPE ANTIFUNGAL DRUGS MARKET, BY DRUG TYPE, 2016-2023 ($MILLION)
  • TABLE 49. EUROPE ANTIFUNGAL DRUGS MARKET, BY THERAPEAUTIC INDICATION, 2016-2023 ($MILLION)
  • TABLE 50. EUROPE ANTIFUNGAL DRUGS MARKET, BY DOSAGE FORMS, 2016-2023 ($MILLION)
  • TABLE 51. ASIA-PACIFIC ANTIFUNGAL DRUGS MARKET, BY COUNTRY, 2016-2023 ($MILLION)
  • TABLE 52. ASIA-PACIFIC ANTIFUNGAL DRUGS MARKET, BY INFECTION TYPE, 2016-2023 ($MILLION)
  • TABLE 53. ASIA-PACIFIC ANTIFUNGAL DRUGS MARKET, BY DRUG TYPE, 2016-2023 ($MILLION)
  • TABLE 54. ASIA-PACIFIC ANTIFUNGAL DRUGS MARKET, BY THERAPEAUTIC INDICATION, 2016-2023 ($MILLION)
  • TABLE 55. ASIA-PACIFIC ANTIFUNGAL DRUGS MARKET, BY DOSAGE FORMS, 2016-2023 ($MILLION)
  • TABLE 56. LAMEA ANTIFUNGAL DRUGS MARKET, BY COUNTRY, 2016-2023 ($MILLION)
  • TABLE 57. LAMEA ANTIFUNGAL DRUGS MARKET, BY INFECTION TYPE, 2016-2023 ($MILLION)
  • TABLE 58. LAMEA ANTIFUNGAL DRUGS MARKET, BY DRUG TYPE, 2016-2023 ($MILLION)
  • TABLE 59. LAMEA ANTIFUNGAL DRUGS MARKET, BY THERAPEAUTIC INDICATION, 2016-2023 ($MILLION)
  • TABLE 60. LAMEA ANTIFUNGAL DRUGS MARKET, BY DOSAGE FORMS, 2016-2023 ($MILLION)
  • TABLE 61. PFIZER: COMPANY SNAPSHOT
  • TABLE 62. PFIZER: OPERATING SEGMENTS
  • TABLE 63. SANOFI: COMPANY SNAPSHOT
  • TABLE 64. SANOFI: OPERATING SEGMENTS
  • TABLE 65. GILEAD: COMPANY SNAPSHOT
  • TABLE 66. GILEAD: OPERATING SEGMENTS
  • TABLE 67. MERCK: COMPANY SNAPSHOT
  • TABLE 68. MERCK: OPERATING SEGMENTS
  • TABLE 69. NOVARTIS: COMPANY SNAPSHOT
  • TABLE 70. NOVARTIS: OPERATING SEGMENTS
  • TABLE 71. ABBOTT: COMPANY SNAPSHOT
  • TABLE 72. ABBOTT: OPERATING SEGMENTS
  • TABLE 73. BAYER: COMPANY SNAPSHOT
  • TABLE 74. BAYER: OPERATING SEGMENTS
  • TABLE 75. SCYNEXIS: COMPANY SNAPSHOT
  • TABLE 76. SCYNEXIS: OPERATING SEGMENTS
  • TABLE 77. ENZON: COMPANY SNAPSHOT
  • TABLE 78. ENZON: OPERATING SEGMENTS
  • TABLE 79. GSK: COMPANY SNAPSHOT
  • TABLE 80. GSK: OPERATING SEGMENTS

List of Figures

  • FIGURE 1. GLOBAL ANTIFUNGAL DRUGS MARKET, 2016-2023
  • FIGURE 2. SEGMENTATION OF ANTIFUNGAL DRUGS MARKET
  • FIGURE 3. TOP INVESTMENT POCKETS IN GLOBAL ANTIFUNGAL DRUGS MARKET
  • FIGURE 4. TOP WINNING STRATEGIES: PERCENTAGE DISTRIBUTION (2014-2017)
  • FIGURE 5. TOP WINNING STRATEGIES: NATURE AND TYPE
  • FIGURE 6. TOP WINNING STRATEGIES: NATURE AND COMPANY
  • FIGURE 7. BARGAINING POWER OF BUYERS
  • FIGURE 8. BARGAINING POWER OF SUPPLIERS
  • FIGURE 9. THREAT OF NEW ENTRANTS
  • FIGURE 10. THREAT OF SUBSTITUTION
  • FIGURE 11. COMPETITIVE RIVALRY
  • FIGURE 12. RESTRAINTS AND DRIVERS: GLOBAL ANTIFUNGAL DRUGS MARKET
  • FIGURE 13. U.S. ANTIFUNGAL DRUGS MARKET, 2016-2023 ($MILLION)
  • FIGURE 14. MEXICO ANTIFUNGAL DRUGS MARKET, 2016-2023 ($MILLION)
  • FIGURE 15. CANADA ANTIFUNGAL DRUGS MARKET, 2016-2023 ($MILLION)
  • FIGURE 16. UK ANTIFUNGAL DRUGS MARKET, 2016-2023 ($MILLION)
  • FIGURE 17. FRANCE ANTIFUNGAL DRUGS MARKET, 2016-2023 ($MILLION)
  • FIGURE 18. GERMANY ANTIFUNGAL DRUGS MARKET, 2016-2023 ($MILLION)
  • FIGURE 19. ITALY ANTIFUNGAL DRUGS MARKET, 2016-2023 ($MILLION)
  • FIGURE 20. SPAIN ANTIFUNGAL DRUGS MARKET, 2016-2023 ($MILLION)
  • FIGURE 21. REST OF EUROPE ANTIFUNGAL DRUGS MARKET, 2016-2023 ($MILLION)
  • FIGURE 22. JAPAN ANTIFUNGAL DRUGS MARKET, 2016-2023 ($MILLION)
  • FIGURE 23. CHINA ANTIFUNGAL DRUGS MARKET, 2016-2023 ($MILLION)
  • FIGURE 24. INDIA ANTIFUNGAL DRUGS MARKET, 2016-2023 ($MILLION)
  • FIGURE 25. AUSTRALIA ANTIFUNGAL DRUGS MARKET, 2016-2023 ($MILLION)
  • FIGURE 26. REST OF ASIA-PACIFIC ANTIFUNGAL DRUGS MARKET, 2016-2023 ($MILLION)
  • FIGURE 27. BRAZIL ANTIFUNGAL DRUGS MARKET, 2016-2023 ($MILLION)
  • FIGURE 28. ARGENTINA ANTIFUNGAL DRUGS MARKET, 2016-2023 ($MILLION)
  • FIGURE 29. SAUDI ARABIA ANTIFUNGAL DRUGS MARKET, 2016-2023 ($MILLION)
  • FIGURE 30. SOUTH AFRICA ANTIFUNGAL DRUGS MARKET, 2016-2023 ($MILLION)
  • FIGURE 31. REST OF LAMEA ANTIFUNGAL DRUGS MARKET, 2016-2023 ($MILLION)
  • FIGURE 32. PFIZER: NET SALES, 2014-2016 ($MILLION)
  • FIGURE 33. PFIZER: REVENUE BY SEGMENT, 2016 (%)
  • FIGURE 34. PFIZER: REVENUE BY GEOGRAPHY, 2016 (%)
  • FIGURE 35. SANOFI: NET SALES, 2014-2016 ($MILLION)
  • FIGURE 36. SANOFI: REVENUE BY SEGMENT, 2016 (%)
  • FIGURE 37. SANOFI: REVENUE BY GEOGRAPHY, 2016 (%)
  • FIGURE 38. GILEAD: NET SALES, 2014-2016 ($MILLION)
  • FIGURE 39. GILEAD: REVENUE BY SEGMENT, 2016 (%)
  • FIGURE 40. GILEAD: REVENUE BY GEOGRAPHY, 2016 (%)
  • FIGURE 41. MERCK: NET SALES, 2014-2016 ($MILLION)
  • FIGURE 42. MERCK: REVENUE BY SEGMENT, 2016 (%)
  • FIGURE 43. MERCK: REVENUE BY GEOGRAPHY, 2016 (%)
  • FIGURE 44. NOVARTIS: NET SALES, 2014-2016 ($MILLION)
  • FIGURE 45. NOVARTIS: REVENUE BY SEGMENT, 2016 (%)
  • FIGURE 46. NOVARTIS: REVENUE BY GEOGRAPHY, 2016 (%)
  • FIGURE 47. ABBOTT: NET SALES, 2014-2016 ($MILLION)
  • FIGURE 48. ABBOTT: REVENUE BY SEGMENT, 2016 (%)
  • FIGURE 49. ABBOTT: REVENUE BY GEOGRAPHY, 2016 (%)
  • FIGURE 50. BAYER: NET SALES, 2014-2016 ($MILLION)
  • FIGURE 51. BAYER: REVENUE BY SEGMENT, 2016 (%)
  • FIGURE 52. BAYER: REVENUE BY GEOGRAPHY, 2016 (%)
  • FIGURE 53. SCYNEXIS: NET SALES, 2014-2016 ($MILLION)
  • FIGURE 54. SCYNEXIS: REVENUE BY SEGMENT, 2016 (%)
  • FIGURE 55. SCYNEXIS: REVENUE BY GEOGRAPHY, 2016 (%)
  • FIGURE 56. ENZON: NET SALES, 2014-2016 ($MILLION)
  • FIGURE 57. ENZON: REVENUE BY SEGMENT, 2016 (%)
  • FIGURE 58. ENZON: REVENUE BY GEOGRAPHY, 2016 (%)
  • FIGURE 59. GSK: NET SALES, 2014-2016 ($MILLION)
  • FIGURE 60. GSK: REVENUE BY SEGMENT, 2016 (%)
  • FIGURE 61. GSK: REVENUE BY GEOGRAPHY, 2016 (%)
Back to Top